Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab with Radiotherapy and Adjuvant Pembrolizumab in Patients with High-Risk, Localized Soft Tissue Sarcoma of the Extremity
Study Type: Treatment
Phase: II
NCTID: NCT03092323
Principal Investigator:
Benjamin Powers
A Phase 2 Study of DS-8201a NSC 807708 in Adolescents, or Young Adults with Recurrent HER2+ Osteosarcoma
Study Type: Treatment
Phase: II
NCTID: NCT04616560
Principal Investigator:
Kevin Ginn
A Phase 2, Multicenter, Open-label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma RMS, Non-rhabdomyosarcoma Soft Tissue Sarcoma NRSTS and Ewing Sarcoma EWS
Study Type: Treatment
Phase: II
NCTID: NCT03441360
Principal Investigator:
Kevin Ginn
Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone: A Prospective Randomized Controlled Trial
Study Type: Treatment
Phase: III
NCTID: NCT03295981
Principal Investigator:
Kyle Sweeney
A Randomized Phase III Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide VINO-AC Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide VINO-CPO vs Vincristine, Dactinomycin and Cyclophosphamide VAC plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma HR-RMS
Study Type: Treatment
Phase: III
NCTID: NCT04994132
Principal Investigator:
Keith August
Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of brigimadlin BI 907828 treatment in patients with treatment-na�ve or pre-treated advanced dedifferentiated liposarcoma
Study Type: Treatment
Phase: III
NCTID: NCT06058793
Principal Investigator:
Benjamin Powers
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide VAC Alternating with Vincristine and Irinotecan VI versus VAC/VI plus Temsirolimus TORI, Torisel, NSC 683864 in Patients with Intermediate Risk IR Rhabdomyosarcoma RMS
Study Type: Treatment
Phase: III
NCTID: NCT02567435
Principal Investigator:
Keith August
A Prospective Phase III Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma
Study Type: Treatment
Phase: III
NCTID: NCT05304585
Principal Investigator:
Keith August
A Multicenter, Randomized, Placebo-controlled, Double-blind Study of DCC-3014 to Assess the Efficacy and Safety in Patients with Tenosynovial Giant Cell Tumor
Study Type: Treatment
Phase: III
NCTID: NCT05059262
Principal Investigator:
Benjamin Powers
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma
Study Type: Treatment
Phase: III
NCTID: NCT05235165
Principal Investigator:
Keith August